BIIB · Q1 2026 Earnings
BullishBiogen
Reported April 6, 2026
30-second summary
Biogen reaffirmed its FY2026 revenue and EPS outlook while reframing the entire trajectory around the pending Apellis acquisition, with management asserting the deal "allows Biogen to start growing now" and is accretive to non-GAAP EPS in FY2027. New 2026 dilution is real and quantified — $120–$130M of non-GAAP other income/expense headwind from financing plus a $145M ($0.80 EPS) Q2 IPR&D charge — and contract manufacturing revenue has been re-phased to roughly two-thirds in H1, suggesting a softer H2 contribution than the prior even-split framing. The narrative has flipped from "pipeline coming on a flat business" (Q4 FY2025) to "pipeline coming on a growing business" — the most assertively forward-leaning tone in over a year.
Guidance
Biogen reaffirms FY2026 revenue outlook and maintains EPS guidance range, but reveals significant 2026 headwinds ($120–$130M Appellus impact, $145M IPR&D charges in Q2) offset by 2027 accretion and front-loaded contract manufacturing phasing.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Expected Appellus transaction impact on non-GAAP and other income expense | FY2026 | $120 to $130 million (2026) | — |
| Appellus transaction accretion | FY2027 | accretive to non-GAAP EPS in 2027 | — |
| Acquired IPR&D charges | Q2FY2026 | $145 million ($0.80 EPS impact) | — |
| Core operating expenses | Q2FY2026 | roughly consistent with Q1 | — |
| LeCAMBI iClick PDUFA date | Q2FY2026 | May 24th | — |
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Contract manufacturing revenue | FY2026 | roughly $300 million in each half ($600 million implied full year) | roughly $600 million phased as roughly two-thirds in first half | Explicit $600M full-year (previously implicit), with front-loaded phasing: ~$400M H1 vs prior $300M H1 | Raised |
Management tone
Q2 FY2025 launches lead, MS resilient → Q3 FY2025 launches at $1.2B TTM, deliberate BD expansion → Q4 FY2025 managed-decline operating model → Q1 FY2026 pipeline coming on a growing business
The four-quarter arc has now completed a full inversion. In Q4 FY2025 management explicitly committed to a declining top line as the cost of an EPS-growth thesis; one quarter later, the framing is that Apellis transforms the trajectory from flat to growing, with the late-stage pipeline arriving on a growing base rather than a shrinking one. The anchor is direct: "Before, we had a pipeline coming on a flat business. Now, I see a pipeline coming on a growing business. And I think that's the fundamental difference in what the Apellis acquisition does for us." This is the most assertive forward-looking claim Biogen has made in this coverage window. The signal: management is willing to stake credibility on a near-term growth re-acceleration enabled by M&A — the rhetorical opposite of the Q4 framing.
Nephrology has migrated across three quarters from "felzartamab in four indications" abstract pipeline language (Q3 FY2025) to "ready to go in nephrology...going to Congresses now with a marketed product and not a future product" (Q1 FY2026). The anchor: "If you went back six, seven years ago, nobody was interested in nephrology...within Povelli and with the addition of the Apellus team, we have a whole team ready to go." The shift signals the company now positions nephrology as a core commercial franchise with immediate revenue and physician-relationship capability — not a 2027+ readout-dependent option. This recasts what investors should pay for: an operating franchise rather than a probability-weighted Phase 3 asset.
The Leqembi narrative has compounded across four quarters: build infrastructure → market-creating → "game changer" iClick → multiple near-term inflection points. Management on iClick: "We have a PDUFA date of May 24th for the induction subcutaneous...this is going to be an opportunity to facilitate the care pathway, improve patient convenience." The PDUFA date has moved from forward-flag to operating-quarter event. A positive May 24 outcome materially expands the addressable practice base before the H2 FY2026 reimbursement cliff.
Geographic atrophy framing also moved this quarter — from a visual-acuity-outcome product to disease-progression-prevention positioning. Management's framing of GA as preventing blindness rather than improving acuity reframes the patient and payer conversation for Syfovre, which Biogen will inherit through Apellis. This is the kind of label-positioning work that suggests commercial integration has been thought through, not improvised.
The one defensive note: management's "10% strategy, 90% execution" framing and explicit reference to integration risk acknowledge that the bullish narrative now rests on operating delivery, not strategic positioning.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Andrew Tai · Jefferies
Filing strategy for SLE: Would you file immediately if both Phase IIIs are positive, or wait for CLE data? File one or two NDAs? What if only one SLE study hits significance?
Management indicated filing would be approached as a package deal. While they don't typically comment on filing strategy, they noted precedent exists for one positive/one negative trial outcome and would examine totality of data. Remains optimistic given breakthrough designations and positive Phase II CLE data.
Michael Yee · UBS
BIB80 study was downsized from 700 to ~400 patients. What type of trend would justify advancing to Phase III vs. signaling lack of investment if trend is weak?
Management discussed go-no-go criteria established well ahead of readout. Primary endpoint is CDR sum of boxes with multiple dosing regimens/frequencies examined. Emphasized will look at totality of data including tau reduction (tau-PET), CDR movement, and clinical signals. Acknowledged uncertainty on required magnitude of effect and patient population identification. Positioned as pioneering study where whole field will learn from results.
Salveen Richter · Goldman Sachs
Update on blood-based biomarker adoption for Lecanemab and patient switching from Kisunla to Lecanemab maintenance.
Blood-based biomarkers growing at same clip as 2025 adoption. CMS now allows reimbursement confirmation via blood biomarkers. PCP pilot with Biogen and ACI shows higher usage in pilot territories. Kisunla patients reaching 18-month mark in Q1; physicians exploring switches to Lecanemab maintenance, though no data available yet. Patients generally want to stay on therapy; physician and patient fear of cognitive decline drives continuance.
Brian Abrams · RBC Capital Markets
What signals will you look for in BIB80 data, and how much could further improvements in administration form impact the program?
Management explained BIB80 is an ASO targeting tau with ability to hit both intracellular and extracellular compartments (vs. prior antibody approaches). Phase 1B showed tau reduction. CELIA proof-of-concept will determine if tau reduction translates to clinical benefit on cognition. Exploring multiple dosing regimens and treatment frequencies. Recently acquired Alcyon to explore alternative delivery options beyond intrathecal.
Terence Flynn · Morgan Stanley
Falzadumab acquisition of China rights for $100M with significant back-end milestones. What does this mean for commercial opportunity in China and globally vs. consensus?
Management outlined large TAM for rare kidney diseases (ICGMN, AMR, pMGN, C3G) with limited epidemiologic clarity. AMR market ~11,000 patients; at IGAN pricing (~$350K/year), TAM $2-3B. Phase II showed 80% AMR resolution. MDI (5-6K patients) adds incremental opportunity. Falzadumab targets CD38+ plasma cells; advantages include early targeting in disease cascade, durability (18-month durability observed post 9 infusions Phase II), and disease-modifying profile. Readouts expected 2027.
Answers to last quarter's watch list
What to watch into next quarter
Apellis deal close and Q2 IPR&D charge. $145M ($0.80 EPS) Q2 charge is committed ($0.55 TJBio/felzartamab China + $0.25 Stellar1 milestone); watch whether deal closes on the timeline implied and whether the $120–$130M FY OI&E impact lands at the low or high end as financing terms finalize. Funding structure: $3.6B cash + $2B new borrowings, with $2B repayment targeted by end of 2027.
Leqembi iClick PDUFA outcome May 24. Approval is the operating event of Q2; a CRL or delay would meaningfully damage the "growing business" framing because iClick is the lever for U.S. Leqembi acceleration.
BIIB080 CELIA Phase 2 mid-year readout. Tau reduction is the threshold biomarker; cognition signal on CDR-SB is the higher bar. Read-throughs to primary tauopathies on the horizon.
H2 FY2026 contract manufacturing pacing. Implied ~$200M H2 vs ~$400M H1 — watch whether Q3 trajectory confirms the step-down or whether management revises the phasing again.
Whether the FY2026 EPS range holds with $145M Q2 IPR&D and $120–$130M OI&E now embedded. The reaffirmed $15.25–$16.25 range absorbs material new headwinds — the Q2 print is the first test of whether the underlying business is strong enough to support that absorption.
Apellis commercial integration evidence. Management's "ready to go in nephrology" framing requires Syfovre, Empaveli, and felzartamab revenue trajectories to validate. Watch Q2/Q3 contribution disclosures once the deal closes.
Q2 MS revenue cadence. First clean read on whether the mid-teen FY decline is front-loaded (consistent with Tysabri biosimilar EU and Tecfidera Europe timing) or building through the year.
Spinraza high-dose conversion durability. First-month ~20% start-form rate is strong; watch whether it sustains and whether ex-US momentum builds beyond Germany.
Felzartamab AMR Phase 3 progression toward 2027 readout. With nephrology now positioned as a core franchise and TAM scaffolding (~$2–3B in AMR alone) on the table, any incremental disclosure on AMR trial timing, enrollment, or competitive entrants becomes higher-stakes.
Sources
- Biogen Q1 FY2026 earnings press release (Form 8-K cover page): https://www.sec.gov/Archives/edgar/data/875045/000087504526000039/R1.htm
- Biogen Q1 FY2026 earnings call transcript (prepared remarks and Q&A), April 6, 2026.
- Prior-quarter Tapebrief briefs (Q4 FY2025, Q3 FY2025, Q2 FY2025) for trend context.
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.